SynthesisFrontiers in endocrinology2026
Research progress of short stature and advanced bone age, early-onset osteoarthritis and osteochondritis dissecans (SSOAOD) caused by acan gene mutation.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Familial short stature: genetic architecture, risk stratification, and precision management.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Heterozygous mutations in the Methods: This summary synthesizes current clinical evidence and management approaches for ACAN-related short stature. Recombinant human growth hormone (rhGH) is the primary treatment used to improve height in affected children. Clinical management also integrates growth promotion, joint protection, genetic counseling, and screening of at-risk family members. Results: rhGH therapy provides moderate improvement in height, but its efficacy decreases with increasing age. Long-term safety of rhGH on joint health remains unclear. The disease spectrum illustrates progressive severity from short stature alone to significant skeletal and joint pathology. Discussion: Clinical care should adopt a multidisciplinary approach combining growth promotion, joint protection, and genetic counseling, including screening for at-risk family members. Future multicenter, long-term follow-up studies are needed to further clarify the molecular mechanisms of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.